变应性支气管肺曲霉病治疗的研究进展  

Research progress in treatment of allergic bronchopulmonary aspergillosis

作　　者：李潇瑶 张铭贤 陈小雪 张焕萍[2] LI Xiaoyao;ZHANG Mingxian;CHEN Xiaoxue;ZHANG Huanping(Department of Pulmonary and Critical Care Medicine,Third Hospital of Shanxi Medical University,Taiyuan 030032,China;Department of Allergy,Third Hospital of Shanxi Medical University,Taiyuan 030032,China)

机构地区：[1]山西医科大学第三医院呼吸与危重症医学科,太原030032 [2]山西医科大学第三医院过敏反应科,太原030032

出　　处：《中国临床新医学》2024年第12期1419-1422,共4页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：山西省自然科学研究面上项目(编号:202203021211067)。

摘　　要：变应性支气管肺曲霉病(ABPA)是机体对曲霉抗原(主要是烟曲霉)过敏而引起的变态反应性肺部炎性疾病,主要特征为反复发作的难以控制的喘息、咳嗽及咳痰,血清总免疫球蛋白E显著升高以及肺内浸润和近端支气管扩张。ABPA患者未及时治疗,可能出现进展性呼吸衰竭,甚至死亡等。该文对ABPA治疗的研究进展作一综述。Allergic bronchopulmonary aspergillosis(ABPA)is an allergic pulmonary inflammatory disease caused by allergy to Aspergillus antigen(mainly Aspergillus fumigatus).ABPA is characterized by recurrent difficult-to-control wheezing,coughing,expectorating,significantly elevated serum total immunoglobulin E,and pulmonary infiltration and proximal bronchiectasis.The ABPA patients who are not treated promptly may develop progressive respiratory failure and even die.In this paper,the research progress in treatment of ABPA is reviewed.

关 键 词：变态反应 支气管肺曲霉病 真菌 治疗 

分 类 号：R562[医药卫生—呼吸系统]